Üsküdar university
Istanbul, Üsküdar, 34662, Turkey (Türkiye)
NCT Number: NCT07680049
Fatigue, balance impairment, and fear of falling are common problems in individuals with Multiple Sclerosis (MS). Previous studies have shown significant associations among these variables; however, the mechanisms underlying the relationship between fatigue and fear of falling remain unclear. It is possible that fatigue increases fear of falling indirectly through its negative effects on balance performance.
Trial opening soon.
Get Notified18 year–75 year
All sexes
Observational
Istanbul, Üsküdar, 34662, Turkey (Türkiye)
Multiple sclerosis (MS) is a chronic demyelinating and neurodegenerative disease of the central nervous system that frequently leads to fatigue, balance impairment, and fear of falling. These symptoms negatively affect mobility, independence, participation in daily activities, and quality of life. Fatigue is one of the most common and disabling symptoms in individuals with MS and may contribute to impaired balance and an increased risk of falls.
Fear of falling is highly prevalent in people with MS and is associated with reduced physical activity, activity avoidance, and functional decline. Balance impairment is another common manifestation of MS and may represent an important mechanism linking fatigue to fear of falling. However, although fatigue, balance, and fear of falling have been investigated separately, the mediating role of balance in the relationship between fatigue and fear of falling has not been sufficiently explored.
The aim of this cross-sectional observational study is to investigate whether balance mediates the relationship between fatigue and fear of falling in individuals with multiple sclerosis. Fatigue will be assessed using the Fatigue Severity Scale (FSS), balance performance will be evaluated using the Mini-Balance Evaluation Systems Test (Mini-BESTest), and fear of falling will be measured using the Falls Efficacy Scale-International (FES-I).
The findings of this study are expected to improve the understanding of the mechanisms underlying fear of falling in individuals with MS and provide evidence to support the development of rehabilitation programs targeting balance to reduce fear of falling and improve functional outcomes.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Observational Model: Cross-Sectional
Time frame: Time Frame: Baseline (single assessment)
Fear of falling will be assessed using the Falls Efficacy Scale-International (FES-I). The FES-I is a 16-item questionnaire that evaluates concern about falling during a range of daily activities. Total scores range from 16 to 64, with higher scores indicating greater fear of falling.
Time frame: Baseline (single assessment)
Fatigue severity will be assessed using the Fatigue Severity Scale (FSS). The FSS consists of 9 items rated on a 7-point Likert scale. The total score is calculated as the mean of all items, with higher scores indicating greater fatigue severity.
Time frame: Baseline (single assessment)
Balance performance will be evaluated using the Mini-Balance Evaluation Systems Test (Mini-BESTest). The Mini-BESTest consists of 14 items assessing dynamic balance. Total scores range from 0 to 28, with higher scores indicating better balance performance.
Contact information is provided by the study sponsor or research team.
günay çimen aysal, phd
CONTACT
osman çoban, phD
CONTACT
Uskudar University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07666958
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Prague, Czech Republic, Czechia
View Trial DetailsNCT07589062
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Abu Dhabi, United Arab Emirates
View Trial DetailsNCT07562074
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Calgary, Alberta, Canada
View Trial DetailsNCT07555379
Ataxia, Autoimmune Diseases
Sharjah city, United Arab Emirates
View Trial Details